氟马西尼对ICU低活动型谵妄的影响:一项双盲、安慰剂对照先导研究
这项单中心、双盲、随机安慰剂对照先导研究纳入苯二氮䓬暴露且符合CAM-ICU和RASS评估的低活动型谵妄成人ICU患者。患者先接受氟马西尼试验剂量(0.1 mg静脉起始,每5分钟递增0.1 mg,最大总量2 mg),RASS评分增加大于1分者为反应者,随机接受氟马西尼(0.05-0.3 mg/hr)或安慰剂输注最长72小时。25例中22例(88%)对试验剂量有反应。两组14天内无谵妄且无昏迷的存活天数中位数相似(12.7 vs 9.2,p=0.19),14天内谵妄缓解概率无差异(90% vs 70%,p=0.2),ICU住院时间无差异。无严重不良事件。作者认为氟马西尼试验剂量和输注是苯二氮䓬相关低活动型谵妄的潜在选择,但可能获益未知,需更大研究进一步评估。
要点
- 苯二氮䓬暴露的低活动型谵妄成人ICU患者中,25例接受氟马西尼试验剂量,22例(88%)RASS评分增加大于1分,判为反应者。
- 反应者随机接受氟马西尼(0.05-0.3 mg/hr)或安慰剂输注最长72小时,14天内无谵妄且无昏迷的存活天数中位数12.7 vs 9.2天(p=0.19),无统计学差异。
- 14天内谵妄缓解概率氟马西尼组90% vs 安慰剂组70%(p=0.2),无统计学差异。
- 研究药物输注结束时无谵妄且无昏迷天数的比值比0.17(95%CI 0.022-1.23,p=0.079),未达统计学显著。
- 两组ICU住院时间无差异(7.8±4.8 vs 7±8天,p=0.74),无严重不良事件发生。
适用人群与场景
- 美国一家大型学术医学中心成人ICU的成人危重患者,需有苯二氮䓬暴露,且基于CAM-ICU和RASS评估存在低活动型谵妄。
诊断标准与关键阈值
- 低活动型谵妄基于Confusion Assessment Method-ICU(CAM-ICU)和Richmond Agitation Sedation Scale(RASS)评估判定。
- 试验剂量反应者定义为RASS评分增加大于1分。
处置流程与药物剂量
- 氟马西尼试验剂量从0.1 mg静脉起始,每5分钟递增0.1 mg,最大总剂量2 mg。
- RASS评分增加大于1分者为反应者,随机接受氟马西尼0.05-0.3 mg/hr或安慰剂输注,最长72小时。
- CAM-ICU评分每日评估两次以判断谵妄是否缓解。
研究设计与关键结果
- 单中心、双盲、随机安慰剂对照先导研究,25例患者中22例(88%)对氟马西尼试验剂量有反应。
- 入组后14天内无谵妄且无昏迷的存活天数中位数两组相似(12.7 vs 9.2,p=0.19)。
- 14天内谵妄缓解概率氟马西尼组90% vs 安慰剂组70%(p=0.2),无统计学差异。
- 研究药物输注结束时无谵妄且无昏迷天数的比值比0.17(95%CI 0.022-1.23,p=0.079),未达统计学显著。
- ICU住院时间两组无差异(7.8±4.8 vs 7±8天,p=0.74)。
- 无严重不良事件发生。
- 试验基于观察到的效应量和把握度分析提前终止。
证据类型、等级与局限
- 证据类型:单中心、双盲、随机安慰剂对照先导研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,氟马西尼试验剂量和输注是苯二氮䓬暴露相关低活动型谵妄的潜在选择,但可能获益未知。
- 作者认为,需更大规模研究进一步评估这些发现。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: To determine whether the use of flumazenil reverses hypoactive delirium and increases delirium-free days in critically ill patients who were exposed to benzodiazepine therapy during the ICU admission.
DESIGN: This was a single-center, double-blinded, randomized placebo-controlled pilot study.
SETTING: Adult ICUs at a large academic medical center in the United States.
PATIENTS: Adult, critically ill patients with benzodiazepine exposure and hypoactive delirium based on the Confusion Assessment Method-ICU and Richmond Agitation Sedation Scale assessments were considered for enrollment.
INTERVENTIONS: Patients received a test dose of flumazenil starting at 0.1 mg intravenously and titrated up every 5 minutes by 0.1 mg increments up to a maximum total dose of 2 mg. Patients who demonstrated a Richmond Agitation Sedation Scale score increase of greater than 1 point were considered responders and randomized to flumazenil (0.05-0.3 mg/hr) or placebo infusion for up to 72 hours. Confusion Assessment Method-ICU scores were assessed twice daily for resolution of delirium.
MEASUREMENTS AND MAIN RESULTS: The trial was stopped early based on the observed size effect and power analysis. Twenty-two of the 25 patients responded to the flumazenil test dose (88%). The median number of delirium-free days alive without coma within 14 days of enrollment was similar between the two infusion groups (12.7 vs 9.2; p = 0.19). There was no difference in the probability of delirium resolution within the first 14 days with 90% versus 70% in the flumazenil and placebo groups, respectively (p = 0.2). There was no statistical difference (odds ratio, 0.17; 95% CI, 0.022-1.23; p = 0.079) in delirium- and coma-free days at the end of the study drug infusion. There was no difference between groups in ICU length of stay (7.8 ± 4.8 vs 7 ± 8; p = 0.74). No serious adverse events occurred.
CONCLUSIONS: This study found that flumazenil test dose and infusion present a potential option for hypoactive delirium associated with benzodiazepine exposure; however, the possible benefit is unknown. Larger studies are warranted to further evaluate these findings.
参考来源
- Schomer KJ, Duby JJ, Firestone RL, et al. Effect of Flumazenil on Hypoactive Delirium in the ICU: A Double-Blind, Placebo-Controlled Pilot Study. Crit Care Explor. 2020. PMID: 32259108. doi:10.1097/CCE.0000000000000085
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。